{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T06:45:22Z","timestamp":1744181122897},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,7,26]],"date-time":"2016-07-26T00:00:00Z","timestamp":1469491200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical Co., Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s12185-016-2070-7","type":"journal-article","created":{"date-parts":[[2016,7,26]],"date-time":"2016-07-26T08:30:50Z","timestamp":1469521850000},"page":"596-604","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Phase I dose escalation study of high dose carfilzomib monotherapy for Japanese patients with relapsed or refractory multiple myeloma"],"prefix":"10.1007","volume":"104","author":[{"given":"Shinsuke","family":"Iida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensei","family":"Tobinai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Taniwaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihisa","family":"Shumiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Chou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,26]]},"reference":[{"key":"2070_CR1","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s12185-011-0917-5","volume":"94","author":"T Hideshima","year":"2011","unstructured":"Hideshima T, Anderson KC. Novel therapies in MM: from the aspect of preclinical studies. Int J Hematol. 2011;94:344\u201354.","journal-title":"Int J Hematol"},{"key":"2070_CR2","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516\u201320.","journal-title":"Blood"},{"key":"2070_CR3","doi-asserted-by":"crossref","first-page":"867","DOI":"10.4065\/79.7.867","volume":"79","author":"SK Kumar","year":"2004","unstructured":"Kumar SK, Therneau TM, Gertz MA, Lacy MQ, Dispenzieri A, Rajkumar SV, et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc. 2004;79:867\u201374.","journal-title":"Mayo Clin Proc"},{"key":"2070_CR4","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1158\/0008-5472.CAN-06-4086","volume":"67","author":"SD Demo","year":"2007","unstructured":"Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 2007;67:6383\u201391.","journal-title":"Cancer Res"},{"key":"2070_CR5","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","volume":"120","author":"DS Siegel","year":"2012","unstructured":"Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012;120:2817\u201325.","journal-title":"Blood"},{"key":"2070_CR6","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, \u0160pi\u010dka I, Oriol A, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372:142\u201352.","journal-title":"N Engl J Med"},{"key":"2070_CR7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","volume":"17","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hajek R, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17:27\u201338.","journal-title":"Lancet Oncol"},{"key":"2070_CR8","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/bjh.13900","volume":"172","author":"T Watanabe","year":"2016","unstructured":"Watanabe T, Tobinai K, Matsumoto M, Suzuki K, Sunami K, Ishida T, et al. Phase 1\/2 study of carfilzomib in Japanese patients with relapsed and\/or refractory multiple myeloma. Br J Haematol. 2016;172:745\u201356.","journal-title":"Br J Haematol"},{"key":"2070_CR9","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1124\/dmd.111.039164","volume":"39","author":"J Yang","year":"2011","unstructured":"Yang J, Wang Z, Fang Y, Jiang J, Zhao F, Wong H, et al. Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats. Drug Metab Dispos. 2011;39:1873\u201382.","journal-title":"Drug Metab Dispos"},{"key":"2070_CR10","doi-asserted-by":"crossref","first-page":"Abstract 2607","DOI":"10.1158\/1538-7445.AM2011-2607","volume":"71","author":"J Jiang","year":"2011","unstructured":"Jiang J, Kirk CJ, Muchamuel T, Lee S. The benefits of irreversibility: Infusion administration of carfilzomib results in potent proteasome inhibition and improved safety in animals. Cancer Res. 2011;71:Abstract 2607.","journal-title":"Cancer Res"},{"key":"2070_CR11","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1200\/JCO.2013.52.3522","volume":"33","author":"KP Papadopoulos","year":"2015","unstructured":"Papadopoulos KP, Siegel DS, Vesole DH, Lee P, Rosen ST, Zojwalla N, et al. Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and\/or refractory multiple myeloma. J Clin Oncol. 2015;33:732\u20139.","journal-title":"J Clin Oncol"},{"key":"2070_CR12","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS, Blad\u00e9 J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467\u201373.","journal-title":"Leukemia"},{"key":"2070_CR13","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","volume":"102","author":"J Blad\u00e9","year":"1998","unstructured":"Blad\u00e9 J, Samson D, Reece D, Apperley J, Bj\u00f6rkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102:1115\u201323.","journal-title":"Br J Haematol"},{"key":"2070_CR14","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/01621459.1927.10502953","volume":"22","author":"EB Willson","year":"1927","unstructured":"Willson EB. Probable inference, the law of succession, and statistical inference. J Am Stat Assoc. 1927;22:209\u201312.","journal-title":"J Am Stat Assoc."},{"key":"2070_CR15","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1349-7006.2007.00638.x","volume":"99","author":"Y Ogawa","year":"2008","unstructured":"Ogawa Y, Tobinai K, Ogura M, Ando K, Tsuchiya T, Kobayashi Y, et al. Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma. Cancer Sci. 2008;99:140\u20134.","journal-title":"Cancer Sci"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-016-2070-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-016-2070-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-016-2070-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T12:39:22Z","timestamp":1718714362000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-016-2070-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,26]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["2070"],"URL":"https:\/\/doi.org\/10.1007\/s12185-016-2070-7","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,26]]}}}